Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs

Miguel Fribourg, José L. Moreno, Terrell Holloway, Davide Provasi, Lia Baki, Rahul Mahajan, Gyu Park, Scott K. Adney, Candice Hatcher, José M. Eltit, Jeffrey D. Ruta, Laura Albizu, Zheng Li, Adrienne Umali, Jihyun Shim, Alexandre Fabiato, Alexander D. MacKerell, Vladimir Brezina, Stuart C. Sealfon, Marta Filizola, Javier González-Maeso, Diomedes E. Logothetis

Index: Cell 147(5) , 1011-23, (2011)

Full Text: HTML

Abstract

Atypical antipsychotic drugs, such as clozapine and risperidone, have a high affinity for the serotonin 5-HT2A G protein-coupled receptor (GPCR), the 2AR, which signals via a Gq heterotrimeric G protein. The closely related non-antipsychotic drugs, such as ritanserin and methysergide, also block 2AR function, but they lack comparable neuropsychological effects. Why some but not all 2AR inhibitors exhibit antipsychotic properties remains unresolved. We now show that a heteromeric complex between the 2AR and the Gi-linked GPCR, metabotropic glutamate 2 receptor (mGluR2), integrates ligand input, modulating signaling output and behavioral changes. Serotonergic and glutamatergic drugs bind the mGluR2/2AR heterocomplex, which then balances Gi- and Gq-dependent signaling. We find that the mGluR2/2AR-mediated changes in Gi and Gq activity predict the psychoactive behavioral effects of a variety of pharmocological compounds. These observations provide mechanistic insight into antipsychotic action that may advance therapeutic strategies for disorders including schizophrenia and dementia.